AI assistant
Sending…
RESMED INC — Director's Dealing 2017
Feb 7, 2017
30071_dirs_2017-02-07_c740bc88-745d-4f62-8932-89bd7a008230.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2017-02-06
Reporting Person: FARRELL PETER C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-06 | ResMed Common Stock | M | 20000 | $33.70 | Acquired | 321557 | Direct |
| 2017-02-06 | ResMed Common Stock | S | 20000 | $68.321 | Disposed | 301557 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-06 | Resmed Stock Option Plan | $33.70 | M | 20000 | Disposed | 2017-11-11 | ResMed Common Stock (20000) | Direct |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan.
F2: This transaction was executed in multiple trades at prices ranging from 67.58 to 68.58. The price reported above represents the weighted average sales price.
F3: Represents date options first became exercisable. Options vested 1/4 per year.
More from RESMED INC
Regulatory Filings
2026
May 26
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Earnings Release
2026
Jan 29